Clinical scales in progressive MS: Predicting long-term disability

Multiple Sclerosis Journal

Volumn 18, Issue 3, 2012, Pages 345-350

  Bosma, Libertje V A E ^a   Kragt, Jolijn J ^a   Knol, Dirk L ^a   Polman, Chris H ^a   Uitdehaag, Bernard M J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

9 Hole Peg Test; Expanded Disability Status Scale; Guy's Neurological Disability Scale; multiple sclerosis; outcome measurement; progressive; Timed 25 Foot Walk

Indexed keywords

BETA INTERFERON; GLATIRAMER; METHOTREXATE;

ADULT; ARTICLE; DISEASE COURSE; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PREDICTION;

EID: 84857825091     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511419880     Document Type: Article

References (15)

1. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain. 1997 ; 120: 1085-1085
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2002 ; 359: 1221-1231 (Pubitemid 34304266)
3. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006 ; 129: 584-584
4. Rudick RA, Kappos L. Measuring disability in relapsing-remitting MS. Neurology. 2010 ; 75: 296-297
5. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452 (Pubitemid 14237132)
6. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999 ; 122: 871-882 (Pubitemid 29219261)
7. Sharrack B, Hughes RA. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler. 1999 ; 5: 223-223
8. Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain. 2000 ; 123: 1027-1027
9. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 ; 46: 907-907
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-227
11. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005 ; 58: 840-840
12. Lechner-Scott J, Kappos L, Hofman M, et al. Can the Expanded Disability Status Scale be assessed by telephone?. Mult Scler. 2003 ; 9: 154-154
13. Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999 ; 122: 625-625
14. Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol. 2001 ; 58: 961-961
15. Solari A, Radice D, Manneschi L, Motti L, Montanari E. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci. 2005 ; 228: 71-71